All doses of Eli Lilly & Co.’s blockbuster new drugs to treat diabetes and weight loss are available in the US after more than a year and a half of shortages.. The Food and Drug Administration ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

Weight loss drugs have become quite popular in the past years. However, there are a few aspects of the drug that need to be ...

Originally developed for diabetes, GLP-1 therapies have shown to reduce weight by up to 20% in trials. Some analysts estimate that the market for these therapies could hit $150 billion in revenues ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Weight loss drugs help manage blood sugar levels by mimicking two important hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) that regulate insulin ...

Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious conditions such as dementia and stroke, a new study has indicated. At such a ...

Innovent Biologics, the first Chinese firm to gain approval for a GLP-1 weight loss and diabetes drug, has partnered with JD ...

Prescriptions for Mounjaro jabs, to help people lose weight, will be available at GP surgeries in England from today - but ...

(Reuters) -All doses of Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are now available, the U.S. Food and Drug Administration's updated shortage list showed on Friday. However ...